NASDAQ: ODTX
Odyssey Therapeutics, Inc.CIK 0001882782 · Health Care · SIC 2836 · Biological Products
Each report below shows a 3-bullet preview. Free accounts read 3 full reports a month — narrative summary, section diffs, and EDGAR-cited quotes.
Sign up freeWant to see a complete report first? Today's free report (TRS 10-Q) is open in full — no account needed.
Summary not yet generated.
Summary not yet generated.
Partner
Trade ODTX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Odyssey Therapeutics posts first 10-Q: $175.7M cash, $38.3M quarterly loss, runway into H2 2028
5 material changes detected. Sign up free to read the summary.
Summary not yet generated.
Latest financial statements
From 10-Q filed Jun 17, 2026 (period ending Mar 31, 2026). SEC XBRL (companyfacts) — not generated by the model.
Consolidated Statements of Operations (Unaudited)
| Description | Q1 ended Mar 31, 2026 | Q1 ended Mar 31, 2025 |
|---|---|---|
| Revenue: | ||
| Total revenue / net sales | — | 1.9 |
| Operating expenses: | ||
| Research and development | 32.3 | 38.8 |
| General and administrative | 7.3 | 8.0 |
| Total operating expenses | 39.8 | 41.1 |
| Operating income | (39.8) | (39.2) |
| Interest expense | 0.01 | — |
| Other income/(expense), net | 1.6 | 0.9 |
| Income before income taxes | (38.2) | (38.3) |
| Income tax expense/(benefit) | 0.06 | 0.1 |
| Net income | (38.3) | (38.4) |
| Basic earnings per share | (6.77) | (39.37) |
| Diluted earnings per share | (6.77) | (39.37) |
Consolidated Balance Sheets (Unaudited)
| Description | Mar 31, 2026 | Dec 31, 2025 |
|---|---|---|
| Current assets: | ||
| Cash and equivalents | 35.7 | 41.7 |
| Short-term investments | 140.0 | 139.7 |
| Accounts receivable, net | — | — |
| Prepaid expenses and other current assets | 9.4 | 9.3 |
| Total current assets | 185.1 | 190.7 |
| Property, plant and equipment, net | 6.6 | 7.2 |
| Operating lease right-of-use assets, net | 17.9 | 18.8 |
| Finite-lived intangible assets, net | 0.2 | 0.3 |
| Goodwill | 14.1 | 14.3 |
| Deferred income taxes and other assets | 5.3 | 3.3 |
| Other long-term assets | — | 35.2 |
| TOTAL ASSETS | 229.1 | 269.8 |
| Current liabilities: | ||
| Accounts payable | 8.2 | 7.9 |
| Current portion of operating lease liabilities | 5.4 | 5.2 |
| Accrued liabilities | 8.6 | 13.4 |
| Total current liabilities | 22.2 | 26.5 |
| Operating lease liabilities | 20.8 | 21.9 |
| Other long-term liabilities | 6.2 | 6.1 |
| Total liabilities | 49.2 | 54.5 |
| Shareholders' equity: | ||
| Common stock | — | — |
| Capital in excess of stated value | 82.9 | 79.6 |
| Accumulated other comprehensive income (loss) | (0.1) | 0.2 |
| Retained earnings (deficit) | (606.4) | (568.1) |
| Total shareholders' equity | (523.7) | (488.3) |
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | 229.1 | 269.8 |
Consolidated Statements of Cash Flows (Unaudited)
| Description | Q1 ended Mar 31, 2026 | Q1 ended Mar 31, 2025 |
|---|---|---|
| Operating Activities: | ||
| Net cash from operating activities | (41.0) | (38.6) |
| Investing Activities: | ||
| Net cash from investing activities | 34.8 | 34.1 |
| Financing Activities: | ||
| Net cash from financing activities | 0.5 | 0.2 |
| Net increase/(decrease) in cash | (5.7) | (4.2) |
Amounts in millions USD; EPS as reported. Line labels are presentation-friendly mappings of filer XBRL tags — not a re-audit of the full statements. Use EDGAR for interactive notes and detail. Interactive statements & notes on EDGAR ↗